Prone positioning and medication adherence in cancer survivors: A quality-improvement audit
Published
March 15, 2025
Paper ID
PAP-000214
Status
Published
DOI
10.65712/tmj.test000472
Advance Services
Abstract
Background: Earlier studies of prone positioning were small or single-centre. Methods: Eligible participants were cancer survivors. Results: The adjusted odds ratio was 0.48 (95% CI 0.28 to 0.95). Serious adverse events were rare and similar between groups. Conclusion: Implementation will depend on staffing, cost and local protocols.
Introduction
The cost of medication adherence to health systems is substantial. Practice around prone positioning varies widely between centres.
Practice around prone positioning varies widely between centres. Earlier studies of prone positioning were small or single-centre.
Materials and Methods
The primary outcome was medication adherence, assessed blind to allocation. Eligible participants were cancer survivors.
Missing data were handled with multiple imputation. Analyses were adjusted for age, sex and baseline severity. Eligible participants were cancer survivors.
Results
The adjusted odds ratio was 0.51 (95% CI 0.33 to 0.81). 1247 participants were included (median age 39 years). 1913 participants were included (median age 58 years).
Effects were consistent across prespecified subgroups. 4342 participants were included (median age 38 years).
| Group | n | Events | Rate % |
|---|---|---|---|
| Female | 519 | 120 | 23.3 |
| Intervention | 406 | 39 | 29.7 |
| Centre A | 242 | 115 | 18.4 |
| Control | 412 | 11 | 27.3 |
| Control | 506 | 61 | 7.5 |
| Intervention | 559 | 10 | 10.4 |
| Age < 65 | 807 | 119 | 21.4 |
Values are n (%) unless stated otherwise.

Shown for cancer survivors; error bars are 95% confidence intervals.
364 participants were included (median age 48 years). The adjusted odds ratio was 0.60 (95% CI 0.32 to 0.69).
medication adherence occurred in 15% of the intervention group versus 12% of controls. 138 participants were included (median age 59 years). 4350 participants were included (median age 51 years). medication adherence occurred in 22% of the intervention group versus 23% of controls.
Discussion
Implementation will depend on staffing, cost and local protocols. Future work should test prone positioning in a pragmatic multicentre trial.
Residual confounding cannot be excluded. Future work should test prone positioning in a pragmatic multicentre trial. Strengths include the sample size and blinded outcome assessment.
Implementation will depend on staffing, cost and local protocols. Residual confounding cannot be excluded. Strengths include the sample size and blinded outcome assessment.
Future work should test prone positioning in a pragmatic multicentre trial. Residual confounding cannot be excluded. Implementation will depend on staffing, cost and local protocols.
Future work should test prone positioning in a pragmatic multicentre trial. These findings suggest that prone positioning is associated with better medication adherence in cancer survivors.
Conclusions
Prone positioning may be offered for cancer survivors to improve medication adherence.
References
1. Volkov O, Herrera D, et al. Early enteral nutrition and patient satisfaction. Lancet. 2023;321(11):511-1684.
2. Mueller P, Mensah I, et al. Tranexamic acid and patient satisfaction. BMJ. 2013;105(7):572-912.
3. Mueller H, Haddad I, et al. SGLT2 inhibitors and ventilator-free days. N Engl J Med. 2021;242(6):74-1345.
4. Silva T, Tanaka E, et al. Frailty screening and glycaemic control. Eur Heart J. 2022;224(4):869-1181.
5. Silva Y, Nakamura E, et al. Early enteral nutrition and length of stay. N Engl J Med. 2013;12(8):210-1647.
6. Rossi I, Farouk H, et al. Machine-learning triage and post-operative delirium. Ann Intern Med. 2018;308(11):74-1783.
7. Kim C, Volkov Z, et al. Tranexamic acid and post-operative delirium. Crit Care Med. 2025;15(2):140-1486.
Appendices
The statistical analysis plan is in the online supplement.